Role of High Mobility Group Box 1 in Cardiovascular Diseases.
HMGB1
angiogenesis.
cardiovascular
diabetes
inflammation
Journal
Inflammation
ISSN: 1573-2576
Titre abrégé: Inflammation
Pays: United States
ID NLM: 7600105
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
13
10
2021
accepted:
28
03
2022
revised:
27
02
2022
pubmed:
8
4
2022
medline:
28
9
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
High Mobility Group Box 1 (HMGB1) is a ubiquitous, highly conserved nuclear and cytosolic protein that has diverse biological roles depending on its cellular location and posttranslational modifications. The HMGB1 is localized in the nucleus but can be translocated to the cytoplasm to modulate the intracellular signaling and eventually secreted outside the cells. It is widely established that HMGB1 plays a key role in inflammation; however, the role of HMGB1 in the cardiovascular diseases is not well understood. In this review, we will discuss the latest reports on the pathophysiological link between HMGB1 and cardiovascular complications, with special emphasis on the inflammation. Thus, the understanding of the role of HMGB1 may provide new insights into developing new HMGB1-based therapies.
Identifiants
pubmed: 35386038
doi: 10.1007/s10753-022-01668-3
pii: 10.1007/s10753-022-01668-3
doi:
Substances chimiques
HMGB1 Protein
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1864-1874Subventions
Organisme : NIH HHS
ID : HL150014
Pays : United States
Organisme : NIH HHS
ID : HL151616
Pays : United States
Organisme : NIH HHS
ID : HL150014
Pays : United States
Organisme : NIH HHS
ID : HL151616
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Goodwin, G.H., C. Sanders, and E.W. Johns. 1973. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. European Journal of Biochemistry 38: 14–19.
pubmed: 4774120
doi: 10.1111/j.1432-1033.1973.tb03026.x
Calogero, S., F. Grassi, A. Aguzzi, T. Voigtländer, P. Ferrier, S. Ferrari, et al. 1999. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nature Genetics 22: 276–280.
pubmed: 10391216
doi: 10.1038/10338
Tang, D., R. Kang, W. Xiao, H. Wang, S.K. Calderwood, and X. Xiao. 2007. The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. The Journal of Immunology 179: 1236–1244.
pubmed: 17617616
doi: 10.4049/jimmunol.179.2.1236
Scaffidi, P., T. Misteli, and M.E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191–195.
pubmed: 12110890
doi: 10.1038/nature00858
Wakabayashi, A., M. Shimizu, E. Shinya, and H. Takahashi. 2018. HMGB1 released from intestinal epithelia damaged by cholera toxin adjuvant contributes to activation of mucosal dendritic cells and induction of intestinal cytotoxic T lymphocytes and IgA. Cell Death & Disease 9: 631.
doi: 10.1038/s41419-018-0665-z
Yang, H., D.J. Antoine, U. Andersson, and K.J. Tracey. 2013. The many faces of HMGB1: Molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. Journal of Leukocyte Biology 93: 865–873.
pubmed: 23446148
pmcid: 4051189
doi: 10.1189/jlb.1212662
Yang, H., H. Wang, S.S. Chavan, and U. Andersson. 2015. High Mobility Group Box Protein 1 (HMGB1): The prototypical endogenous danger molecule. Molecular Medicine 21 (Suppl 1): S6-s12.
pubmed: 26605648
pmcid: 4661054
doi: 10.2119/molmed.2015.00087
Stumbo, A.C., E. Cortez, C.A. Rodrigues, M. Henriques, L.C. Porto, H.S. Barbosa, et al. 2008. Mitochondrial localization of non-histone protein HMGB1 during human endothelial cell-Toxoplasma gondii infection. Cell Biology International 32: 235–238.
pubmed: 17936030
doi: 10.1016/j.cellbi.2007.08.031
Malarkey, C.S., and M.E. Churchill. 2012. The high mobility group box: The ultimate utility player of a cell. Trends in Biochemical Sciences 37: 553–562.
pubmed: 23153957
pmcid: 4437563
doi: 10.1016/j.tibs.2012.09.003
Wahid, A., W. Chen, X. Wang, and X. Tang. 2021. High-mobility group box 1 serves as an inflammation driver of cardiovascular disease. Biomedicine and Pharmacotheraphy 139:111555.
Magna, M., and D.S. Pisetsky. 2014. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Molecular Medicine 20: 138–146.
pubmed: 24531836
pmcid: 3966993
doi: 10.2119/molmed.2013.00164
Lu, B., D.J. Antoine, K. Kwan, P. Lundbäck, H. Wähämaa, H. Schierbeck, et al. 2014. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America 111: 3068–3073.
pubmed: 24469805
pmcid: 3939889
doi: 10.1073/pnas.1316925111
Andersson, U., H. Wang, K. Palmblad, A.C. Aveberger, O. Bloom, H. Erlandsson-Harris, et al. 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. Journal of Experimental Medicine 192: 565–570.
pubmed: 10952726
pmcid: 2193240
doi: 10.1084/jem.192.4.565
Kim, J.B., J. Sig Choi, Y.M. Yu, K. Nam, C.S. Piao, S.W. Kim, et al. 2006. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. Journal of Neuroscience 26: 6413–6421.
pubmed: 16775128
doi: 10.1523/JNEUROSCI.3815-05.2006
Wang, C., J. Jiang, X. Zhang, L. Song, K. Sun, and R. Xu. 2016. Inhibiting HMGB1 reduces cerebral ischemia reperfusion injury in diabetic mice. Inflammation 39: 1862–1870.
pubmed: 27596007
doi: 10.1007/s10753-016-0418-z
Andersson, U., H. Yang, and H. Harris. 2018. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opinion on Therapeutic Targets 22: 263–277.
pubmed: 29447008
doi: 10.1080/14728222.2018.1439924
Andersson, U., H. Yang, and H. Harris. 2018. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Seminars in Immunology 38: 40–48.
pubmed: 29530410
doi: 10.1016/j.smim.2018.02.011
Yang, H., H.S. Hreggvidsdottir, K. Palmblad, H. Wang, M. Ochani, J. Li, et al. 2010. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proceedings of the National Academy of Sciences of the United States of America 107: 11942–11947.
pubmed: 20547845
pmcid: 2900689
doi: 10.1073/pnas.1003893107
Andrassy, M., H.C. Volz, J.C. Igwe, B. Funke, S.N. Eichberger, Z. Kaya, et al. 2008. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216–3226.
pubmed: 18574060
doi: 10.1161/CIRCULATIONAHA.108.769331
Oozawa, S., S. Mori, T. Kanke, H. Takahashi, K. Liu, Y. Tomono, et al. 2008. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circulation Journal 72: 1178–1184.
pubmed: 18577832
doi: 10.1253/circj.72.1178
Higashikuni, Y., K. Tanaka, M. Kato, O. Nureki, Y. Hirata, R. Nagai, et al. 2013. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation. Journal of the American Heart Association 2:e000267.
Zhang, L., M. Liu, H. Jiang, Y. Yu, P. Yu, R. Tong, et al. 2016. Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure. Journal of Cellular and Molecular Medicine 20: 459–470.
pubmed: 26647902
doi: 10.1111/jcmm.12743
Su, F.F., M.Q. Shi, W.G. Guo, X.T. Liu, H.T. Wang, Z.F. Lu, et al. 2012. High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes. Mediators of Inflammation 2012:805149.
Funayama, A., T. Shishido, S. Netsu, T. Narumi, S. Kadowaki, H. Takahashi, et al. 2013. Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure. Cardiovascular Research 99: 657–664.
pubmed: 23708738
pmcid: 3746952
doi: 10.1093/cvr/cvt128
Limana, F., A. Germani, A. Zacheo, J. Kajstura, A. Di Carlo, G. Borsellino, et al. 2005. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circulation Research 97: e73-83.
pubmed: 16166556
doi: 10.1161/01.RES.0000186276.06104.04
Kitahara, T., Y. Takeishi, M. Harada, T. Niizeki, S. Suzuki, T. Sasaki, et al. 2008. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovascular Research 80: 40–46.
pubmed: 18558628
doi: 10.1093/cvr/cvn163
Kaya, Z., M. Afanasyeva, Y. Wang, K.M. Dohmen, J. Schlichting, T. Tretter, et al. 2001. Contribution of the innate immune system to autoimmune myocarditis: A role for complement. Nature Immunology 2: 739–745.
pubmed: 11477411
doi: 10.1038/90686
Heymans, S. 2006. Inflammation and cardiac remodeling during viral myocarditis. Ernst Schering Research Found Workshop 197–218.
Eriksson, S., J. Hellman, and K. Pettersson. 2005. Autoantibodies against cardiac troponins. New England Journal of Medicine 352: 98–100.
pubmed: 15635126
doi: 10.1056/NEJM200501063520123
Göser, S., M. Andrassy, S.J. Buss, F. Leuschner, C.H. Volz, R. Ottl, et al. 2006. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 114: 1693–1702.
pubmed: 17015788
doi: 10.1161/CIRCULATIONAHA.106.635664
Bangert, A., M. Andrassy, A.M. Müller, M. Bockstahler, A. Fischer, C.H. Volz, et al. 2016. Critical role of RAGE and HMGB1 in inflammatory heart disease. Proceedings of the National Academy of Sciences of the United States of America 113: E155–E164.
pubmed: 26715748
Su, Z., P. Zhang, Y. Yu, H. Lu, Y. Liu, P. Ni, et al. 2016. HMGB1 facilitated macrophage reprogramming towards a proinflammatory M1-like phenotype in experimental autoimmune myocarditis development. Science and Reports 6: 21884.
doi: 10.1038/srep21884
Kohno, T., T. Anzai, K. Naito, T. Miyasho, M. Okamoto, H. Yokota, et al. 2009. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovascular Research 81: 565–573.
pubmed: 18984601
doi: 10.1093/cvr/cvn291
Yu, P., M. Liu, B. Zhang, Y. Yu, E. Su, S. Xie, et al. 2020. Cardiomyocyte-restricted high-mobility group box 1 (HMGB1) deletion leads to small heart and glycolipid metabolic disorder through GR/PGC-1α signalling. Cell Death Discov 6: 106.
pubmed: 33101708
pmcid: 7575537
doi: 10.1038/s41420-020-00340-9
Wu, R.N., T.Y. Yu, J.C. Zhou, M. Li, H.K. Gao, C. Zhao, et al. 2018. Targeting HMGB1 ameliorates cardiac fibrosis through restoring TLR2-mediated autophagy suppression in myocardial fibroblasts. International Journal of Cardiology 267: 156–162.
pubmed: 29957254
doi: 10.1016/j.ijcard.2018.04.103
Uehara, R., and E.D. Belay. 2012. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. Journal of Epidemiology 22: 79–85.
pubmed: 22307434
pmcid: 3798585
doi: 10.2188/jea.JE20110131
Hoshina, T., K. Kusuhara, K. Ikeda, Y. Mizuno, M. Saito, and T. Hara. 2008. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease. Scandinavian Journal of Rheumatology 37: 445–449.
pubmed: 18720262
doi: 10.1080/03009740802144143
Qian, B., H. Huang, M. Cheng, T. Qin, T. Chen, and J. Zhao. 2020. Mechanism of HMGB1-RAGE in Kawasaki disease with coronary artery injury. European Journal of Medical Research 25: 8.
pubmed: 32183905
pmcid: 7079349
doi: 10.1186/s40001-020-00406-5
Jia, C., J. Zhang, H. Chen, Y. Zhuge, H. Chen, F. Qian, et al. 2019. Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathespin B signaling pathway and NLRP3 inflammasome activation. Cell Death & Disease 10: 778.
doi: 10.1038/s41419-019-2021-3
Ueno, K., Y. Nomura, Y. Morita, and Y. Kawano. 2021. Prednisolone suppresses the extracellular release of HMGB-1 and associated inflammatory pathways in Kawasaki disease. Frontiers in Immunology 12:640315.
Mitola, S., M. Belleri, C. Urbinati, D. Coltrini, B. Sparatore, M. Pedrazzi, et al. 2006. Cutting edge: Extracellular high mobility group box-1 protein is a proangiogenic cytokine. The Journal of Immunology 176: 12–15.
pubmed: 16365390
doi: 10.4049/jimmunol.176.1.12
Frantz, S., K.A. Vincent, O. Feron, and R.A. Kelly. 2005. Innate immunity and angiogenesis. Circulation Research 96: 15–26.
pubmed: 15637304
doi: 10.1161/01.RES.0000153188.68898.ac
Yuan, K., T.M. Hong, J.J. Chen, W.H. Tsai, and M.T. Lin. 2004. Syndecan-1 up-regulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis. Blood 104: 1025–1033.
pubmed: 15126321
doi: 10.1182/blood-2003-09-3334
Sachdev, U., X. Cui, G. Hong, S. Namkoong, J.M. Karlsson, C.J. Baty, et al. 2012. High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. Journal of Vascular Surgery 55: 180–191.
Sachdev, U., X. Cui, and E. Tzeng. 2013. HMGB1 and TLR4 mediate skeletal muscle recovery in a murine model of hindlimb ischemia. Journal of Vascular Surgery 58: 460–469.
pubmed: 23414695
pmcid: 3657591
doi: 10.1016/j.jvs.2012.11.071
Lu, B., T. Nakamura, K. Inouye, J. Li, Y. Tang, P. Lundbäck, et al. 2012. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488: 670–674.
pubmed: 22801494
pmcid: 4163918
doi: 10.1038/nature11290
Xu, J., X. Cui, J. Li, P. Koutakis, I. Pipinos, E. Tzeng, et al. 2018. Chloroquine improves the response to ischemic muscle injury and increases HMGB1 after arterial ligation. Journal of Vascular Surgery 67: 910–921.
pubmed: 28259568
doi: 10.1016/j.jvs.2017.01.021
Lan, J., H. Luo, R. Wu, J. Wang, B. Zhou, Y. Zhang, et al. 2020. Internalization of HMGB1 (High Mobility Group Box 1) promotes angiogenesis in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 40: 2922–2940.
pubmed: 32998518
doi: 10.1161/ATVBAHA.120.315151
Hansen, L.M., D. Gupta, G. Joseph, D. Weiss, and W.R. Taylor. 2017. The receptor for advanced glycation end products impairs collateral formation in both diabetic and non-diabetic mice. Laboratory Investigation 97: 34–42.
pubmed: 27869797
doi: 10.1038/labinvest.2016.113
Inoue, K., K. Kawahara, K.K. Biswas, K. Ando, K. Mitsudo, M. Nobuyoshi, et al. 2007. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovascular Pathology 16: 136–143.
pubmed: 17502242
doi: 10.1016/j.carpath.2006.11.006
Kanellakis, P., A. Agrotis, T.S. Kyaw, C. Koulis, I. Ahrens, S. Mori, et al. 2011. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 31: 313–319.
pubmed: 21088249
doi: 10.1161/ATVBAHA.110.218669
Ghaffari, S., E. Jang, F. Naderinabi, R. Sanwal, N. Khosraviani, C. Wang, et al. 2021. Endothelial HMGB1 is a critical regulator of LDL transcytosis via an SREBP2-SR-BI axis. Arteriosclerosis, Thrombosis, and Vascular Biology 41: 200–216.
pubmed: 33054399
Zhao, Y., W. Li, and D. Zhang. Gycyrrhizic acid alleviates atherosclerotic lesions in rats with diabetes mellitus. Molecular Medicine Report 24.
Li, Y., H. Li, B. Chen, F. Yang, and Z. Hao. 2021. miR-141–5p suppresses vascular smooth muscle cell inflammation, proliferation, and migration via inhibiting the HMGB1/NF-kappaB pathway. Journal of the Biochemical Molecular Toxicology 35:e22828.
Roshan, M.H., A. Tambo, and N.P. Pace. 2016. The Role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis. International Journal of the Inflammation 2016: 1532832.
doi: 10.1155/2016/1532832
Pahwa, R., B. Adams-Huet, and I. Jialal. 2017. The effect of increasing body mass index on cardio-metabolic risk and biomarkers of oxidative stress and inflammation in nascent metabolic syndrome. Journal of Diabetes and Its Complications 31: 810–813.
pubmed: 28285929
doi: 10.1016/j.jdiacomp.2017.02.010
Pahwa, R., and I. Jialal. 2016. The role of the high-mobility group box1 protein-Toll like receptor pathway in diabetic vascular disease. Journal of Diabetes and Its Complications 30: 1186–1191.
pubmed: 27037040
doi: 10.1016/j.jdiacomp.2016.03.005
Yan, X.X., L. Lu, W.H. Peng, L.J. Wang, Q. Zhang, R.Y. Zhang, et al. 2009. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205: 544–548.
pubmed: 19150066
doi: 10.1016/j.atherosclerosis.2008.12.016
Marjanac, I., R. Lovrić, and J. Barbić. 2019. Serum levels of the high-mobility group box 1 protein (HMGB1) in children with type 1 diabetes mellitus: Case-control study. Central-European Journal of Immunology 44: 33–37.
pubmed: 31114434
pmcid: 6526583
doi: 10.5114/ceji.2019.84012
Giovannini, S., G. Tinelli, F. Biscetti, G. Straface, F. Angelini, D. Pitocco, et al. 2017. Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects. Cardiovascular Diabetology 16: 99.
pubmed: 28789654
pmcid: 5549317
doi: 10.1186/s12933-017-0581-z
Oozawa, S., S. Sano, and M. Nishibori. 2014. Usefulness of high mobility group box 1 protein as a plasma biomarker in patient with peripheral artery disease. Acta Medica Okayama 68: 157–162.
pubmed: 24942794
Biscetti, F., G. Straface, R. De Cristofaro, S. Lancellotti, P. Rizzo, V. Arena, et al. 2010. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 59: 1496–1505.
pubmed: 20200317
pmcid: 2874711
doi: 10.2337/db09-1507
Volz, H.C., C. Seidel, D. Laohachewin, Z. Kaya, O.J. Müller, S.T. Pleger, et al. 2010. HMGB1: The missing link between diabetes mellitus and heart failure. Basic Research in Cardiology 105: 805–820.
pubmed: 20703492
doi: 10.1007/s00395-010-0114-3
Chen, Q., Z.Y. Wang, L.Y. Chen, and H.Y. Hu. 2017. Roles of High Mobility Group Box 1 in cardiovascular calcification. Cellular Physiology and Biochemistry 42: 427–440.
pubmed: 28571029
doi: 10.1159/000477591
Wang, B., G. Wei, B. Liu, X. Zhou, H. Xiao, N. Dong, et al. 2016. The role of High Mobility Group Box 1 protein in interleukin-18-induced myofibroblastic transition of valvular interstitial cells. Cardiology 135: 168–178.
pubmed: 27395056
doi: 10.1159/000447483
Passmore, M., M. Nataatmadja, Y.L. Fung, B. Pearse, S. Gabriel, P. Tesar, et al. 2015. Osteopontin alters endothelial and valvular interstitial cell behaviour in calcific aortic valve stenosis through HMGB1 regulation. European Journal of Cardio-Thoracic Surgery 48: e20–e29.
pubmed: 26273067
doi: 10.1093/ejcts/ezv244
Wang, Y., J. Shan, W. Yang, H. Zheng, and S. Xue. 2013. High mobility group box 1 (HMGB1) mediates high-glucose-induced calcification in vascular smooth muscle cells of saphenous veins. Inflammation 36: 1592–1604.
pubmed: 23928875
doi: 10.1007/s10753-013-9704-1
Chen, Z., R. Li, L.G. Pei, Z.H. Wei, J. Xie, H. Wu, et al. 2021. High-mobility group box-1 promotes vascular calcification in diabetic mice via endoplasmic reticulum stress. Journal of Cellular and Molecular Medicine 25: 3724–3734.
pubmed: 33724642
pmcid: 8051722
doi: 10.1111/jcmm.16075
Sun, Y., C.H. Byon, K. Yuan, J. Chen, X. Mao, J.M. Heath, et al. 2012. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circulation Research 111: 543–552.
pubmed: 22773442
pmcid: 3678289
doi: 10.1161/CIRCRESAHA.112.267237
Lin, M.E., T. Chen, E.M. Leaf, M.Y. Speer, and C.M. Giachelli. 2015. Runx2 expression in smooth muscle cells is required for arterial medial calcification in mice. American Journal of Pathology 185: 1958–1969.
pubmed: 25987250
pmcid: 4484217
doi: 10.1016/j.ajpath.2015.03.020
Byon, C.H., A. Javed, Q. Dai, J.C. Kappes, T.L. Clemens, V.M. Darley-Usmar, et al. 2008. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. Journal of Biological Chemistry 283: 15319–15327.
pubmed: 18378684
pmcid: 2397455
doi: 10.1074/jbc.M800021200
Nebbioso, M., A. Lambiase, M. Armentano, G. Tucciarone, V. Bonfiglio, R. Plateroti, et al. 2020. The complex relationship between diabetic retinopathy and High-Mobility Group Box: a review of molecular pathways and therapeutic strategies. Antioxidants (Basel) 9.
Steinle, J.J. 2020. Role of HMGB1 signaling in the inflammatory process in diabetic retinopathy. Cell Signal 73:109687.
El-Asrar, A.M., M.I. Nawaz, D. Kangave, K. Geboes, M.S. Ola, S. Ahmad, et al. 2011. High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Molecular Vision 17: 1829–1838.
pubmed: 21850157
pmcid: 3137555
Liang, W.J., H.W. Yang, H.N. Liu, W. Qian, and X.L. Chen. 2020. HMGB1 upregulates NF-kB by inhibiting IKB-α and associates with diabetic retinopathy. Life Sciences 241:117146.
Abu El-Asrar, A.M., K. Alam, M. Garcia-Ramirez, A. Ahmad, M.M. Siddiquei, G. Mohammad, et al. 2017. Association of HMGB1 with oxidative stress markers and regulators in PDR. Molecular Vision 23: 853–871.
pubmed: 29259392
pmcid: 5723152
Jiang, Y., L. Liu, E. Curtiss, and J.J. Steinle. 2017. Epac1 blocks NLRP3 inflammasome to reduce IL-1β in retinal endothelial cells and mouse retinal vasculature. Mediators of Inflammation 2017: 2860956.
pubmed: 28348460
pmcid: 5350318
Jiang, Y., L. Liu, and J.J. Steinle. 2018. Epac1 deacetylates HMGB1 through increased IGFBP-3 and SIRT1 levels in the retinal vasculature. Molecular Vision 24: 727–732.
pubmed: 30581279
pmcid: 6279194
Jiang, Y., and J.J. Steinle. 2020. Epac1 requires AMPK phosphorylation to regulate HMGB1 in the retinal vasculature. Investigative Ophthalmology & Visual Science 61: 33.
doi: 10.1167/iovs.61.11.33
Liu, L., Y. Jiang, and J.J. Steinle. 2019. Epac1 and glycyrrhizin both inhibit HMGB1 levels to reduce diabetes-induced neuronal and vascular damage in the mouse retina. Journal of the Clinical Medicine 8.
Luo, F., A. Das, J. Chen, P. Wu, X. Li, and Z. Fang. 2019. Metformin in patients with and without diabetes: A paradigm shift in cardiovascular disease management. Cardiovascular Diabetology 18: 54.
pubmed: 31029144
pmcid: 6486984
doi: 10.1186/s12933-019-0860-y
Tsoyi, K., H.J. Jang, I.T. Nizamutdinova, Y.M. Kim, Y.S. Lee, H.J. Kim, et al. 2011. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. British Journal of the Pharmacology 162:1498–508.
Horiuchi, T., N. Sakata, Y. Narumi, T. Kimura, T. Hayashi, K. Nagano, et al. 2017. Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity. Journal of Biological Chemistry 292: 8436–8446.
pubmed: 28373282
pmcid: 5437248
doi: 10.1074/jbc.M116.769380
Yang, H., H. Wang, and U. Andersson. 2020. Targeting inflammation driven by HMGB1. Frontiers in Immunology 11: 484.
pubmed: 32265930
pmcid: 7099994
doi: 10.3389/fimmu.2020.00484
Zhang, T., X. Hu, Y. Cai, B. Yi, and Z. Wen. 2014. Metformin protects against hyperglycemia-induced cardiomyocytes injury by inhibiting the expressions of receptor for advanced glycation end products and high mobility group box 1 protein. Molecular Biology Reports 41: 1335–1340.
pubmed: 24420848
doi: 10.1007/s11033-013-2979-3
Mollica, L., F. De Marchis, A. Spitaleri, C. Dallacosta, D. Pennacchini, M. Zamai, et al. 2007. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chemistry & Biology 14: 431–441.
doi: 10.1016/j.chembiol.2007.03.007
Gong, G., L. Xiang, L. Yuan, L. Hu, W. Wu, L. Cai, et al. 2014. Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats. PLoS One 9:e89450.
Mohammad, G., M.M. Siddiquei, A. Othman, M. Al-Shabrawey, and A.M. Abu El-Asrar. 2013. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Experimental Eye Research 107: 101–109.
pubmed: 23261684
doi: 10.1016/j.exer.2012.12.009
Abu El-Asrar, A.M., M.M. Siddiquei, M.I. Nawaz, K. Geboes, and G. Mohammad. 2014. The proinflammatory cytokine high-mobility group box-1 mediates retinal neuropathy induced by diabetes. Mediators of Inflammation 2014:746415.
Dandona, P., H. Ghanim, K. Green, C.L. Sia, S. Abuaysheh, N. Kuhadiya, et al. 2013. Insulin infusion suppresses while glucose infusion induces Toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients. American Journal of Physiology, Endocrinology and Metabolism 304: E810–E818.
pubmed: 23403945
doi: 10.1152/ajpendo.00566.2012
Delucchi, F., R. Berni, C. Frati, S. Cavalli, G. Graiani, R. Sala, et al. Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats. PLoS One 7:e39836.
Wu, H., Z. Chen, J. Xie, L.N. Kang, L. Wang, and B. Xu. 2016. High Mobility Group Box-1: A missing link between diabetes and its complications. Mediators of Inflammation 2016: 3896147.
pubmed: 27847406
pmcid: 5099456
Diao, H., Z. Kang, F. Han, and W. Jiang. 2014. Astilbin protects diabetic rat heart against ischemia-reperfusion injury via blockade of HMGB1-dependent NF-κB signaling pathway. Food and Chemical Toxicology 63: 104–110.
pubmed: 24211745
doi: 10.1016/j.fct.2013.10.045
Kikuchi, K., S. Tancharoen, T. Ito, Y. Morimoto-Yamashita, N. Miura, K. Kawahara, et al. 2013. Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. International Journal of Molecular Sciences 14: 18899–18924.
pubmed: 24065095
pmcid: 3794813
doi: 10.3390/ijms140918899